Amarin Corp Plc (AMRN)

[Crikker]

Don’t understand $20 price target even if only easier secondary endpoints met. Especially if 3 Ps (patient, physicians, payer) are happy Company already doing $200 million in sales. At $1 billion with 40% net and 20 P/E ratio = $8 billion market cap or roughly $25 per share. I believe this is grossly underestimating earnings power of this drug.